ETFsXtrackers MSCI Next Generation Internet Innovation UCITS ETF 1C
Xtrackers
Xtrackers MSCI Next Generation Internet Innovation UCITS ETF 1C
XNGI LSEAccumulatingIreland
Last close · EUR
62.59EUR
-4.86% · -€3.20
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
XNGIBase
- Fund charges
- Not publishedFee basis unverified
- Fund size
- Not published
- Return 1Y
- +3.3%
- Sharpe 3Y
- 1.03
- Volatility 1Y
- 22.0%annualised
- Holdings
- 100Fund holdings
Performance
Compare
- XNGI+3.3%
- Price, EUR
Returns
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| XNGI | -14.0% | -5.9% | +3.4% | +8.9% | +3.3% | +82.8% | - |
| MSCI World | -2.8% | -0.6% | +7.8% | +14.3% | +14.1% | +65.6% | +64.8% |
| Gap to MSCI World | -11.2% | -5.2% | -4.5% | -5.4% | -10.7% | +17.2% | - |
Risk and return
Sharpe ratio · 3Y
1.03
Below MSCI World · 1.24- Return p.a.
- +24.5%
- Volatility
- 20.5%
- Max loss
- -27.4%Apr 2025
Sharpe vs indices
MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
XNGI
1.03
MSCI Emerging Markets IMI
0.93
CAC 40
0.37
Method
Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.
Top holdings
- Top 10
- 47.1%
- Holdings
- 100
- As of
- 1VISA CLASS AUS92826C83945.52%
- 2MICROSOFTUS59491810455.31%
- 3APPLEUS03783310055.10%
- 4ADVANCED MICRO DEVICESUS00790310784.85%
- 5META PLATFORMS CLASS AUS30303M10274.74%
- 6AMAZON COM INCUS02313510674.63%
- 7TAIWAN SEMICONDUCTOR MANUFACTURINGUS87403910034.44%
- 8NVIDIAUS67066G10404.25%
- 9BROADCOM INCUS11135F10124.15%
- 10MASTERCARD CLASS AUS57636Q10404.14%
Countries
Classified 100.0%
United States84.1%
TW
CN
KR
- Largest
- 84.1%United States
- Top 3
- 93.7%
- Effective number
- 1.41 / HHI
Market cap
Weight vs holdings
47.1%of the fund sits in the top 10 holdings
47.1%44.4%
WeightHoldings
104050
- Holdings 1-10
- Holdings 11-50
- Holdings 51-100
Size split
Not published
Compare ETFs in Copio.
Factual research, without a suitability score or investment recommendation. Past relationships can change.
